BCL2 and breast cancer: On the other hand, luteolin at low concentrations (as low as 10 μM) was found to attenuate doxorubicin-induced cytotoxicity in breast cancer cells, probably through a combination of antioxidant activity and an increase in the levels of Bcl-2 protein, and breast cancer cells’ viability decreased when luteolin concentrations were increased (>30 μM) [91].